Holen Sie sich die Stockscreener-App
6.0523
0.24%
0.0123
Schlusskurs vom Vortag:
$6.04
Offen:
$6.04
24-Stunden-Volumen:
664.26K
Relative Volume:
0.33
Marktkapitalisierung:
$1.04B
Einnahmen:
$291.85M
Nettoeinkommen (Verlust:
$554.00K
KGV:
-796.36
EPS:
-0.0076
Netto-Cashflow:
$27.93M
1W Leistung:
+8.12%
1M Leistung:
+4.21%
6M Leistung:
-25.53%
1J Leistung:
+37.29%
1-Tages-Spanne:
$5.97
$6.145
1-Wochen-Bereich:
$5.68
$6.145
52-Wochen-Spanne:
$3.805
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.055 | 1.04B | 291.85M | 554.00K | 27.93M | -0.0076 |
VRTX
Vertex Pharmaceuticals Inc
|
433.56 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.84 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.75 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.59 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.86 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation - MSN
XERS Technical Analysis & Stock Price Forecast - Intellectia AI
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - gurufocus.com
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - gurufocus.com
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees - geneonline.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Tudor Investment Corp ET AL Decreases Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Insider Sell: James Brady Sells Shares of Xeris Biopharma Holdin - gurufocus.com
Brady sells Xeris Biopharma (XERS) shares worth $60,035 By Investing.com - au.investing.com
Brady sells Xeris Biopharma (XERS) shares worth $60,035 - investing.com
Xeris Biopharma (XERS) director sells 10,834 shares in Rule 10b5-1 trades - Stock Titan
XERS Stock Price, Quote & Chart | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Aug Macro: Will Xeris Biopharma Holdings Inc stock recover after earningsEntry Point & AI Enhanced Trading Alerts - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard (XERS) disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares - Stock Titan
Revenue per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView
Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4%What's Next? - MarketBeat
Market Review: Can Xeris Biopharma Holdings Inc keep up with sector leaders - baoquankhu1.vn
Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility - AD HOC NEWS
Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook By Investing.com - Investing.com Canada
350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC - MarketBeat
Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise - Stock Titan
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Rosalind Advisors Inc. - MarketBeat
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com
XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - simplywall.st
XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xeris Pharmaceuticals Q2 2025 Earnings Preview - MSN
Momentum Shift: Will Xeris Biopharma Holdings Inc benefit from seasonalityJuly 2025 Update & Stepwise Trade Signal Implementation - baoquankhu1.vn
Xeris Biopharma (NASDAQ:XERS) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends - Markets Mojo
Xeris Biopharma Hits Day Low of $5.80 Amid Price Pressure - Markets Mojo
Why Is CORT Stock Falling Today? - Stocktwits
HC Wainwright Forecasts Xeris Biopharma Q1 Earnings - MarketBeat
Xeris Biopharma (XERS) officer exercises options, lifts share holdings - Stock Titan
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT I - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brady James Aloysius | Director |
Mar 30 '26 |
Sale |
5.54 |
10,834 |
60,036 |
89,166 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):